1. Home
  2. TNXP vs RPID Comparison

TNXP vs RPID Comparison

Compare TNXP & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.65

Market Cap

172.7M

Sector

Health Care

ML Signal

HOLD

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

HOLD

Current Price

$2.20

Market Cap

204.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
RPID
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.7M
204.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TNXP
RPID
Price
$13.65
$2.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
419.1K
283.1K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
2.78
EPS
N/A
N/A
Revenue
$13,107,000.00
$33,587,000.00
Revenue This Year
$558.11
$19.12
Revenue Next Year
$38.29
$18.42
P/E Ratio
N/A
N/A
Revenue Growth
29.85
19.74
52 Week Low
$11.60
$1.86
52 Week High
$69.65
$4.94

Technical Indicators

Market Signals
Indicator
TNXP
RPID
Relative Strength Index (RSI) 46.22 31.83
Support Level $13.32 N/A
Resistance Level $20.36 $4.48
Average True Range (ATR) 1.18 0.20
MACD -0.03 -0.01
Stochastic Oscillator 37.93 19.00

Price Performance

Historical Comparison
TNXP
RPID

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.

Share on Social Networks: